Gilead Sciences (GILD) had its price target raised by Royal Bank Of Canada from $118.00 to $123.00. They now have a "sector perform" rating on the stock.
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets [Yahoo! Finance]
A Look At Gilead Sciences (GILD) Valuation After Recent Mixed Share Price Performance [Yahoo! Finance]
Gilead Extends Tender Offer to Acquire Arcellx